| Literature DB >> 30573952 |
Roberto Burro1, Ugo Savardi1, Maria Antonietta Annunziata2, Paolo De Paoli2, Ivana Bianchi3.
Abstract
BACKGROUND: Healthcare staff should be aware of the importance that patients may attach to the words that are used to convey information. This is relevant in terms of the patients' understanding. Modeling how people understand the information conveyed in a medical context may help health practitioners to better appreciate the patients' approach.Entities:
Keywords: Rasch model; opposites; perceived commitment to the treatment; perceived severity of impairment to health; perception of risk; simulated oncological scenario
Year: 2018 PMID: 30573952 PMCID: PMC6292238 DOI: 10.2147/PPA.S175957
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1The scales relating to ten of the items with a good fit for the three dimensions: impairment to Health (H), Risks involved (R), and the degree of commitment required by the Treatment (T). For the complete list of the items fitting in with each of the three dimensions, see Table S1.
Figure 2Effect plots for Type of Communication (B or U) and Polarity (VN, SN, and NN) resulting from the ANOVA described in the text. Bars represent the 95% CI. Contrasts (Bonferroni) and Cohen’s effect size (d) values are reported within each plot.
Abbreviations: B, bipolar; NN, neither very negative nor slightly negative; SN, slightly negative; U, unipolar; VN, very negative.
Figure 3Mosaic plots showing the frequency of E and I items for the three axes (H, R, T) based on Communication Type (mosaic on the left), Polarity (central mosaic), and Quantity (mosaic on the right). The two levels for Communication Type are B and U. The three levels for Polarity are VN, SN, and NN. The four levels of Quantity are NM, QL, VG, and NO. The color of the tiles corresponds to Pearson residuals and the bars to the right of each mosaic show which color corresponds to residuals greater than the cut-off points |2| (corresponding to a P<0.05).
Abbreviations: B, bipolar; E, excluded; I, included; NM, Numerical; NN, neither very negative nor slightly negative; NO, no quantity; QL, qualitative; SN, slightly negative; U, unipolar; VG, vague; VN, very negative.
Linear models describing the relationships among the dimensions: Health (H), Risks (R), and commitment to the Treatment (T)
| Relationship | Estimate | Standard error | Pr(>|t|) | Multiple | |
|---|---|---|---|---|---|
| R–H | 0.768 | 0.072 | 10.672 | 1.34e-14 | 0.690 |
| T–H | 0.678 | 0.068 | 9.883 | 1.92e-13 | 0.657 |
| T–R | 0.671 | 0.084 | 7.908 | 2.03e-10 | 0.550 |
Note:
P<0.001.
Conversion functions that can be used to make estimates of participants’ responses on other scales
| From | To | Functions |
|---|---|---|
|
| ||
| R | H | H=1.110×R − 0.040 |
| T | H | S=1.221×T − 0.056 |
| T | R | R=1.154×T − 0.034 |
| H | R | R=0.909×H + 0.036 |
| H | T | T=0.819×H + 0.045 |
| R | T | T=0.866× |
Example showing how the locations of the items described in Table S1 can be used to weigh the raw scores provided by a participant on the H scale (thus obtaining the scores reported in the fourth column) and how it is possible to estimate the scores in the other two dimensions (R and T) based on the regression functions in Table 2 (scores reported in the fifth and sixth columns)
| Item | H raw score | H weight/location | H weighted score (raw score × item weight/location) | From weighted H to weighted R | From weighted H to weighted T |
|---|---|---|---|---|---|
|
| |||||
| B16 | 10 | 1.145 | 11.45 | 10.444 | 9.422 |
| B18 | 8 | 0.781 | 6.248 | 5.715 | 5.162 |
| U33 | 6 | 0.558 | 3.348 | 3.079 | 2.787 |
| B13 | 4 | 0.483 | 1.932 | 1.792 | 1.627 |
| B2 | 2 | 0.354 | 0.708 | 0.679 | 0.624 |
Complete list of the items used in the questionnaire and the corresponding classification of each item in terms of Polarity
| Items | Health | Risk | Treatment | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | Text | Polarity | Communication type | QuanQL | Chisq | df | Infit_t | Location | Chisq | df | Infit_t | Location | Chisq | df | Infit_t | Location | |||
| 1 | Medical tests have shown the presence of a small nodule [Le analisi hanno rivelato la presenza di un piccolo nodulo] | B | SN | QL | 493.889 | 469 | 0.206 | 0.7 | 0.329 | 488.687 | 469 | 0.256 | 0.62 | 0.289 | 450.010 | 469 | 0.728 | −0.45 | 0.156 |
| 2 | Medical tests have shown the presence of a large nodule [Le analisi hanno rivelato la presenza di un grosso nodulo] | B | VN | QL | 472.969 | 469 | 0.44 | 0.06 | 0.354 | 436.696 | 469 | 0.855 | −1.21 | 0.399 | 464.345 | 469 | 0.552 | −0.36 | 0.529 |
| 3 | Medical tests have revealed the existence of a benign nodule [Le analisi hanno rivelato la presenza di un nodulo benigno] | B | SN | QL | 495.598 | 469 | 0.191 | 0.76 | 0.000 | 498.017 | 469 | 0.171 | 0.56 | 0.000 | 456.560 | 469 | 0.651 | −0.42 | 0.000 |
| 4 | Medical tests have revealed the existence of a malignant nodule [Le analisi hanno rivelato la presenza di un nodulo maligno] | B | VN | QL | 439.506 | 469 | 0.832 | −1.14 | 0.601 | 393.869 | 469 | 0.995 | −1.84 | 0.589 | 441.653 | 469 | 0.813 | −0.9 | 0.676 |
| 5 | The Magnetic Resonance (MR) scan has revealed some nodules localized in a circumscribed region of your body [La risonanza magnetica ha rivelato la presenza di alcuni noduli localizzati in una zona circoscritta del tuo corpo] | B | SN | QL | 514.008 | 469 | 0.074 | 1.47 | 0.446 | 493.557 | 469 | 0.209 | 0.75 | 0.676 | 475.809 | 469 | 0.404 | 0.03 | 0.410 |
| 6 | The Magnetic Resonance (MR) scan has revealed some nodules in various regions of your body [La risonanza magnetica ha rivelato la presenza di alcuni noduli diffusi in varie zone del tuo corpo] | B | VN | QL | 413.112 | 469 | 0.97 | −1.64 | 0.730 | <a>389.203 | <a>469 | <a>0.997 | <a>−2.17* | <a>0.579 | 434.567 | 469 | 0.871 | −1 | 0.556 |
| 7 | This type of tumor is common [Questo tipo di tumore è comune] | B | SN | QL | 421.369 | 469 | 0.944 | −1.76 | 0.525 | <a>411.818 | <a>469 | <a>0.973 | <a>−2.13* | <a>0.482 | <a>411.818 | <a>469 | <a>0.973 | <a>−2.04* | <a>0.422 |
| 8 | This type of tumor is rare [Questo tipo di tumore è raro] | B | VN | QL | 448.275 | 469 | 0.747 | −0.38 | 0.769 | 400.705 | 469 | 0.99 | −1.7 | 0.673 | 442.304 | 469 | 0.807 | −0.99 | 0.549 |
| 9 | This tumor is easy to treat [Questo tumore è facilmente curabile] | B | SN | QL | <a>569.369 | <a>469 | <a>0.001* | <a>3.60* | <a>0.593 | <a>544.502 | <a>469 | <a>0.009* | <a>2.91* | <a>0.566 | 488.687 | 469 | 0.256 | 0.68 | 0.478 |
| 10 | This tumor is hard to treat [Questo tumore è difficilmente curabile] | B | VN | QL | 454.834 | 469 | 0.672 | −0.18 | 0.826 | 389.203 | 469 | 0.997 | −1.4 | 0.747 | 448.553 | 469 | 0.744 | −0.52 | 0.630 |
| 11 | This type of tumor has a slow progression and takes a long time before it becomes serious enough to cause death [Questo tumore ha una progressione lenta (impiega molto tempo a diventare così grave da condurre alla morte)] | B | SN | QL | 459.522 | 469 | 0.614 | −0.27 | 0.706 | 435.652 | 469 | 0.863 | −1.22 | 0.667 | 440.653 | 469 | 0.822 | −0.61 | 0.484 |
| 12 | This type of tumor has a quick progression and takes very little time to become serious enough to cause death [Questo tumore ha una progressione veloce (impiega poco tempo a diventare così grave da condurre alla morte)] | B | VN | QL | 447.808 | 469 | 0.752 | −0.33 | 0.899 | 414.305 | 469 | 0.967 | −0.95 | 0.918 | 412.693 | 469 | 0.971 | −0.69 | 0.791 |
| 13 | This tumor is always linked to a genetic predisposition [Questo tumore è sempre connesso con una predisposizione genetica] | B | VN | QL | 442.838 | 469 | 0.802 | −1.22 | 0.483 | 436.567 | 469 | 0.856 | −1.21 | 0.445 | 429.872 | 469 | 0.902 | −1.95 | 0.356 |
| 14 | This tumor is never linked to a genetic predisposition [Questo tumore non è mai connesso con una predisposizione genetica] | B | SN | QL | <a>549.472 | <a>469 | <a>0.006* | <a>0.91 | <a>0.724 | 502.320 | 469 | 0.139 | 0.66 | 0.723 | 427.955 | 469 | 0.913 | −1.13 | 0.543 |
| 15 | This tumor is associated with high survival rates [Questo tumore è associato ad alti tassi di sopravvivenza] | B | SN | QL | 477.257 | 469 | 0.386 | 0.25 | 0.332 | 494.904 | 469 | 0.197 | 0.88 | 0.323 | 433.580 | 469 | 0.878 | −1.36 | 0.232 |
| 16 | This tumor is associated with low survival rates [Questo tumore è associato a bassi tassi di sopravvivenza] | B | VN | QL | 483.495 | 469 | 0.312 | −0.31 | 1.145 | 441.543 | 469 | 0.814 | −0.47 | 1.110 | 401.697 | 469 | 0.989 | −0.75 | 0.842 |
| 17 | This treatment will cure this tumor, ie, it will eliminate all of the tumor cells [Questo trattamento curerà il tumore, vale a dire che eliminerà tutte le cellule tumorali] | B | SN | NO | 499.428 | 469 | 0.16 | 0.81 | 0.355 | 465.957 | 469 | 0.531 | −0.21 | 0.241 | 448.737 | 469 | 0.742 | −0.71 | 0.468 |
| 18 | This treatment is palliative in nature, ie, it eliminates the symptoms associated with the tumor [Questo trattamento è palliativo, vale a dire che eliminerà i sintomi associati al tumore] | B | VN | NO | 466.417 | 469 | 0.525 | −0.61 | 0.781 | 487.719 | 469 | 0.266 | −0.09 | 0.712 | 477.989 | 469 | 0.377 | 0.13 | 0.584 |
| 19 | This treatment has high efficacy [Questo trattamento ha un’alta efficacia] | B | SN | QL | 454.917 | 469 | 0.671 | −0.26 | 0.556 | 461.716 | 469 | 0.586 | −0.2 | 0.403 | 426.835 | 469 | 0.919 | −1.54 | 0.369 |
| 20 | This treatment has low efficacy [Questo trattamento ha una bassa efficacia] | B | VN | QL | 427.588 | 469 | 0.915 | −1.3 | 0.517 | 441.543 | 469 | 0.814 | −1.15 | 0.622 | 421.867 | 469 | 0.942 | −1.11 | 0.469 |
| 21 | This treatment is necessary [Questo trattamento è necessario] | B | VN | NO | <a>395.606 | <a>469 | <a>0.994 | <a>−2.4* | <a>0.493 | <a>393.869 | <a>469 | <a>0.995 | <a>−2.6* | <a>0.536 | <a>380.024 | <a>469 | <a>0.999 | <a>−2.18* | <a>0.531 |
| 22 | This treatment is advisable [Questo trattamento è consigliabile] | B | SN | NO | 480.308 | 469 | 0.349 | 0.58 | 0.433 | 462.415 | 469 | 0.577 | −0.08 | 0.617 | 470.950 | 469 | 0.466 | 0.05 | 0.524 |
| 23 | The standard treatment for this tumor has minor adverse side effects [Il trattamento per questo tumore hai dei lievi effetti collaterali] | B | SN | QL | <a>411.361 | <a>469 | <a>0.974 | <a>−2.16* | <a>0.413 | <a>413.520 | <a>469 | <a>0.969 | <a>−2.07* | <a>0.525 | 416.783 | 469 | 0.96 | −1.94 | 0.544 |
| 24 | The standard treatment for this tumor has severe adverse side effects [Il trattamento per questo tumore ha dei seri effetti collaterali] | B | VN | QL | 421.620 | 469 | 0.943 | −1.73 | 0.836 | <a>363.553 | <a>469 | <a>0.999 | <a>−2.38* | <a>0.792 | 436.823 | 469 | 0.854 | −0.75 | 0.819 |
| 25 | The probability of adverse side effects linked to the treatment is very low [La probabilità di effetti collaterali associati al trattamento per questo tumore è molto bassa] | B | SN | QL | <a>406.417 | <a>469 | <a>0.983 | <a>−2.32* | <a>0.461 | 419.786 | 469 | 0.95 | −1.82 | 0.349 | 427.026 | 469 | 0.918 | −1.37 | 0.349 |
| 26 | The probability of adverse side effects linked to the treatment is very high [La probabilità di effetti collaterali associati al trattamento per questo tumore è molto alta] | B | VN | QL | 411.818 | 469 | 0.973 | −1.35 | 0.705 | 434.567 | 469 | 0.871 | −0.6 | 0.674 | 455.083 | 469 | 0.669 | −0.15 | 0.557 |
| 27 | The adverse side effects related to the standard treatment for this tumor have an immediate onset [Gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza immediata] | B | VN | QL | 432.405 | 469 | 0.886 | −1.57 | 0.656 | 431.329 | 469 | 0.893 | −1.27 | 0.785 | 417.741 | 469 | 0.957 | −1 | 0.513 |
| 28 | The adverse side effects related to the standard treatment for this tumor have a delayed onset [Gli effetti collaterali associati al trattamento per questo tumore hanno un’insorgenza ritardata nel tempo] | B | SN | QL | <a>385.691 | <a>469 | <a>0.998 | <a>−2.51* | <a>0.566 | 415.414 | 469 | 0.964 | −1.88 | 0.534 | 413.520 | 469 | 0.969 | −1.68 | 0.549 |
| 29 | The adverse side effects related to the standard treatment are temporary [Gli effetti collaterali associati al trattamento per questo tumore sono temporanei] | B | SN | QL | <a>391.796 | <a>469 | <a>0.996 | <a>−3.06* | <a>0.498 | 420.595 | 469 | 0.947 | −1.87 | 0.524 | <a>401.697 | <a>469 | <a>0.989 | <a>−2.41* | <a>0.521 |
| 30 | The adverse side effects related to the standard treatment are permanent [Gli effetti collaterali associati al trattamento per questo tumore sono permanenti] | B | VN | QL | 409.896 | 469 | 0.977 | −1.79 | 0.655 | 409.373 | 469 | 0.978 | −1.61 | 0.530 | 477.014 | 469 | 0.389 | 0.59 | 0.526 |
| 31 | This treatment requires a short period of time to complete [Il trattamento ha una durata breve] | B | SN | QL | 433.146 | 469 | 0.881 | −1.47 | 0.393 | 439.389 | 469 | 0.833 | −1.22 | 0.332 | 439.738 | 469 | 0.83 | −1.01 | 0.260 |
| 32 | This treatment requires a long period of time to complete [Il trattamento ha una durata lunga] | B | VN | QL | <a>414.684 | <a>469 | <a>0.966 | <a>−2.09* | <a>0.531 | 431.329 | 469 | 0.893 | −1.24 | 0.719 | 403.471 | 469 | 0.987 | −0.75 | 0.651 |
| 33 | This treatment is administered in a single cycle [Il trattamento prevede un unico ciclo di somministrazione] | B | SN | QL | 470.178 | 469 | 0.476 | 0.25 | 0.552 | 487.719 | 469 | 0.266 | 0.73 | 0.551 | 493.667 | 469 | 0.208 | 0.93 | 0.437 |
| 34 | This treatment is administered over many cycles [Il trattamento prevede molti cicli di somministrazione] | B | VN | QL | <a>380.024 | <a>469 | <a>0.999 | <a>−2.53* | <a>0.615 | <a>389.203 | <a>469 | <a>0.997 | <a>−2.57* | <a>0.583 | 454.751 | 469 | 0.673 | −0.16 | 0.430 |
| 35 | This treatment is administered on an outpatient basis [Il trattamento è somministrato in day hospital] | B | SN | NO | <a>413.112 | <a>469 | <a>0.97 | <a>−2.02* | <a>0.424 | 433.436 | 469 | 0.879 | −1.3 | 0.452 | 466.647 | 469 | 0.522 | −0.43 | 0.309 |
| 36 | This treatment is administered on an inpatient basis [Il trattamento prevede ricovero e degenza in ospedale] | B | VN | NO | 442.088 | 469 | 0.809 | −0.76 | 0.658 | 433.146 | 469 | 0.881 | −1.12 | 0.635 | <a>530.339 | <a>469 | <a>0.026* | <a>0.77 | <a>0.591 |
| 37 | During treatment, you can live by yourself, you will not need assistance [Durante il trattamento puoi gestirti autonomamente, non avrai bisogno di assistenza] | B | SN | QL | <a>404.273 | <a>469 | <a>0.986 | <a>−2.48* | <a>0.206 | <a>410.401 | <a>469 | <a>0.976 | <a>−2.22* | <a>0.238 | <a>422.353 | <a>469 | <a>0.94 | <a>−2.1* | <a>0.289 |
| 38 | During treatment, you will need assistance [Durante il trattamento avrai bisogno di assistenza] | B | VN | VG | 456.641 | 469 | 0.65 | −0.51 | 0.506 | 430.692 | 469 | 0.897 | −1.14 | 0.456 | 516.995 | 469 | 0.062 | 0.27 | 0.468 |
| 39 | Once the whole treatment cycle is completed, you can live by yourself, you will not need assistance [Una volta che il trattamento è completato, potrai gestirti autonomamente, non avrai bisogno di assistenza] | B | SN | QL | 472.969 | 469 | 0.44 | 0.08 | 0.539 | 460.231 | 469 | 0.605 | −0.16 | 0.523 | 442.196 | 469 | 0.808 | −0.99 | 0.484 |
| 40 | Once the whole treatment cycle is completed, you will need assistance [Una volta che il trattamento è completato, avrai bisogno di assistenza] | B | VN | VG | 444.495 | 469 | 0.786 | −0.95 | 0.839 | 415.053 | 469 | 0.965 | −1.66 | 0.530 | 441.980 | 469 | 0.81 | −0.59 | 0.780 |
| 41 | During treatment, your lifestyle will remain identical to what it was before treatment [Durante il trattamento il tuo stile di vita non subirà cambiamenti (rimarrà identico a com’era prima del trattamento)] | B | SN | QL | 511.176 | 469 | 0.087 | 1.36 | 0.444 | 491.832 | 469 | 0.225 | 0.89 | 0.358 | 456.070 | 469 | 0.657 | −0.31 | 0.424 |
| 42 | During treatment, your lifestyle will differ from what it was before the treatment [Durante il trattamento il tuo stile di vita subirà dei cambiamenti (non potrà più essere com’era prima del trattamento)] | B | VN | VG | 418.048 | 469 | 0.956 | −1.28 | 0.584 | 418.048 | 469 | 0.956 | −1.42 | 0.494 | 515.952 | 469 | 0.066 | 0.66 | 0.485 |
| 43 | After treatment is completed, your lifestyle will go back to what it was prior to the disease [Dopo il trattamento il tuo stile di vita tornerà identico a com’era prima della malattia] | B | SN | QL | <a>526.423 | <a>469 | <a>0.034* | <a>1.93 | <a>0.461 | 506.367 | 469 | 0.113 | 1.36 | 0.344 | 482.531 | 469 | 0.323 | 0.49 | 0.515 |
| 44 | After treatment is completed, your lifestyle will change from what it was prior to the disease [Dopo il trattamento il tuo stile di vita subirà dei cambiamenti rispetto a com’era prima della malattia] | B | VN | VG | 430.203 | 469 | 0.9 | −0.94 | 0.687 | 448.182 | 469 | 0.748 | −0.63 | 0.498 | 439.970 | 469 | 0.828 | −0.68 | 0.458 |
| 45 | The treatment does not impact on your ability to work (ie, during the treatment phase, you can keep working) [Il trattamento, mentre lo fai, non avrà ripercussioni sulla tua possibilità di lavorare (durante il trattamento potrai continuare ad andare al lavoro)] | B | SN | QL | 428.316 | 469 | 0.911 | −1.78 | 0.340 | 456.884 | 469 | 0.647 | −0.73 | 0.252 | 446.571 | 469 | 0.765 | −0.96 | 0.356 |
| 46 | The treatment impacts on your ability to work (ie, during the treatment phase, you cannot go to work) [Il trattamento, mentre lo fai, avrà ripercussioni sulla tua possibilità di lavorare (durante il trattamento non potrai andare a lavorare)] | B | VN | VG | 393.869 | 469 | 0.995 | −1.65 | 0.750 | 408.266 | 469 | 0.98 | −1.84 | 0.637 | 441.653 | 469 | 0.813 | −0.75 | 0.677 |
| 47 | Once the entire treatment cycle is completed, the treatment will have no impact on your ability to work (you can return to work as you did before the disease) [Una volta che l’intero ciclo di trattamento è finito, non avrai ripercussioni sulla tua attività lavorativa (potrai tornare a lavorare come prima della malattia)] | B | SN | QL | 447.526 | 469 | 0.755 | −0.74 | 0.264 | 436.823 | 469 | 0.854 | −1.18 | 0.288 | 434.979 | 469 | 0.868 | −1.24 | 0.304 |
| 48 | Once the entire treatment cycle is completed, the treatment will have an impact on your ability to work (you will not be able to return to work) [Una volta che l’intero ciclo di trattamento è finito, avrai ripercussioni sulla tua attività lavorativa (non potrai tornare a lavorare come prima della malattia)] | B | VN | VG | 455.907 | 469 | 0.659 | −0.61 | 0.751 | 442.838 | 469 | 0.802 | −0.86 | 0.728 | 469.408 | 469 | 0.486 | −0.45 | 0.720 |
| 1 | Medical tests have shown the presence of a 0.5 inch long nodule (1.3 cm) [Le analisi hanno rivelato la presenza di un nodulo di 1.3 cm] | U | SN | NM | 498.523 | 469 | 0.167 | 0.91 | 0.039 | 507.396 | 469 | 0.107 | 1.17 | 0.294 | 519.861 | 469 | 0.052 | 1.62 | 0.090 |
| 2 | Medical tests have shown the presence of a three inch long nodule (7.6 cm) [Le analisi hanno rivelato la presenza di un nodulo di 7.6 cm] | U | VN | NM | 504.580 | 469 | 0.124 | 1.27 | 0.466 | 519.861 | 469 | 0.052 | 1.72 | 0.659 | 517.264 | 469 | 0.061 | 1.46 | 0.458 |
| 3 | Medical tests demonstrated the existence of a nodule [Le analisi hanno rivelato la presenza di un nodulo] | U | NN | QL | 477.095 | 469 | 0.388 | 0.22 | 0.203 | 497.767 | 469 | 0.173 | 0.89 | 0.212 | <a>534.729 | <a>469 | <a>0.019* | <a>2.14* | <a>0.366 |
| 4 | The Magnetic Resonance (MR) scan has revealed some nodules in your body [La risonanza magnetica ha rivelato la presenza di alcuni noduli nel tuo corpo] | U | NN | QL | <a>551.641 | <a>469 | <a>0.005* | <a>2.52* | <a>0.515 | <a>557.526 | <a>469 | <a>0.003* | <a>2.85* | <a>0.553 | 496.544 | 469 | 0.183 | 0.7 | 0.414 |
| 5 | This tumor affects 1 in a thousand people [Questo tipo di tumore colpisce 1 persona su 1,000] | U | SN | NM | <a>538.830 | <a>469 | <a>0.014* | <a>2.56* | <a>0.424 | <a>539.802 | <a>469 | <a>0.013* | <a>2.38* | <a>0.525 | 486.210 | 469 | 0.282 | 0.81 | 0.381 |
| 6 | This tumor affects 1 in a million people [Questo tipo di tumore colpisce 1 persona su 1,000,000] | U | VN | NM | <a>562.016 | <a>469 | <a>0.002* | <a>2.62* | <a>0.524 | <a>545.968 | <a>469 | <a>0.008* | <a>2.38* | <a>0.574 | <a>554.245 | <a>469 | <a>0.004* | <a>2.07* | <a>0.443 |
| 7 | This tumor is curable in 10% of all cases [Questo tumore è curabile nel 10% dei casi] | U | VN | NM | <a>611.241 | <a>469 | <a>0.001* | <a>0.88 | <a>0.784 | <a>523.969 | <a>469 | <a>0.04* | <a>0.55 | <a>0.799 | 496.068 | 469 | 0.187 | 0.28 | 0.653 |
| 8 | This tumor is curable in 80% of all cases [Questo tumore è curabile nell 80% dei casi] | U | SN | NM | <a>554.245 | <a>469 | <a>0.004* | <a>2.86* | <a>0.384 | <a>569.369 | <a>469 | <a>0.001* | <a>3.18* | <a>0.676 | 508.838 | 469 | 0.099 | 0.87 | 0.316 |
| 9 | This type of tumor usually leads to death within two years of the time of diagnosis [Questo tumore generalmente conduce alla morte in 2 anni dalla diagnosi] | U | VN | NM | <a>525.568 | <a>469 | <a>0.036* | <a>1.25 | <a>0.710 | 513.098 | 469 | 0.078 | 0.75 | 0.888 | <a>537.056 | <a>469 | <a>0.016* | <a>0.68 | <a>0.684 |
| 10 | This type of tumor usually leads to death within ten years of diagnosis [Questo tumore generalmente conduce alla morte in 10 anni dalla diagnosi] | U | SN | NM | <a>538.830 | <a>469 | <a>0.014* | <a>2.54* | <a>0.535 | <a>611.241 | <a>469 | <a>0.001* | <a>3.82* | <a>0.457 | <a>538.830 | <a>469 | <a>0.014* | <a>1.89 | <a>0.519 |
| 11 | This tumor is determined by a specific genetic predisposition in 5 out of 5 cases [Questo tumore ha una predisposizione genetica in 5 casi su 5] | U | VN | NM | <a>528.270 | <a>469 | <a>0.03* | <a>1.94 | <a>0.539 | <a>537.056 | <a>469 | <a>0.016* | <a>2.4* | <a>0.527 | 507.049 | 469 | 0.109 | 1.47 | 0.429 |
| 12 | This tumor is determined by a specific genetic predisposition in 0 out of 5 cases [Questo tumore ha una predisposizione genetica in 0 casi su 5] | U | SN | NM | <a>611.241 | <a>469 | <a>0.001 | <a>3.23* | <a>0.611 | <a>611.241 | <a>469 | <a>0.001* | <a>3.39* | <a>0.670 | <a>611.241 | <a>469 | <a>0.001* | <a>2.54* | <a>0.624 |
| 13 | This tumor has a 70% survival rate [Questo tumore ha un tasso di sopravvivenza del 70%] | U | SN | NM | 502.032 | 469 | 0.141 | 1.01 | 0.248 | 513.549 | 469 | 0.076 | 1.45 | 0.215 | <a>537.917 | <a>469 | <a>0.015* | <a>1.75 | <a>0.221 |
| 14 | This tumor has a 30% survival rate [Questo tumore ha un tasso di sopravvivenza del 30%] | U | VN | NM | 494.563 | 469 | 0.2 | 0.55 | 0.557 | 463.034 | 469 | 0.569 | 0.26 | 0.610 | 477.744 | 469 | 0.38 | 0.4 | 0.623 |
| 15 | This treatment will be of some help with this tumor [Questo trattamento sarà di qualche aiuto in questa situazione] | U | NN | VG | 481.667 | 469 | 0.333 | 0.33 | 0.415 | 478.480 | 469 | 0.371 | 0 | 0.567 | 493.778 | 469 | 0.207 | 0.15 | 0.505 |
| 16 | This treatment has 70% efficacy rate [Questo trattamento ha un’efficacia del 70%] | U | SN | NM | 471.569 | 469 | 0.458 | 0.03 | 0.418 | 476.129 | 469 | 0.4 | 0.17 | 0.441 | 495.019 | 469 | 0.196 | 0.8 | 0.256 |
| 17 | This treatment has a 30% efficacy rate [Questo trattamento ha un’efficacia del 30%] | U | VN | NM | 508.107 | 469 | 0.103 | 1.05 | 0.596 | 494.449 | 469 | 0.201 | 0.89 | 0.567 | 488.201 | 469 | 0.261 | 0.74 | 0.444 |
| 18 | This is a possible course of treatment [Questo è un possibile trattamento] | U | NN | NO | 486.396 | 469 | 0.28 | 0.51 | 0.350 | 461.327 | 469 | 0.591 | −0.27 | 0.512 | 477.907 | 469 | 0.378 | 0.12 | 0.366 |
| 19 | The standard treatment for this tumor has adverse side effects [Il trattamento per questo tumore ha degli effetti collaterali] | U | NN | VG | 442.518 | 469 | 0.805 | −0.97 | 0.427 | 468.948 | 469 | 0.492 | −0.16 | 0.478 | 460.702 | 469 | 0.599 | −0.4 | 0.398 |
| 20 | The probability of adverse side effects relating to the treatment is 1 in 100,000 [La probabilità di effetti collaterali associati al trattamento per questo tumore è di 1 su 100.000] | U | SN | NM | 486.396 | 469 | 0.28 | 0.55 | 0.319 | 517.813 | 469 | 0.059 | 1.53 | 0.224 | 510.972 | 469 | 0.088 | 1.16 | 0.274 |
| 21 | The probability of adverse side effects relating to the treatment is 1 in 100 [La probabilità di effetti collaterali associati al trattamento per questo tumore è di 1 su 100] | U | VN | NM | 519.556 | 469 | 0.053 | 1.53 | 0.365 | <a>531.478 | <a>469 | <a>0.024* | <a>2.17* | <a>0.356 | <a>569.369 | <a>469 | <a>0.001* | <a>2.74* | <a>0.386 |
| 22 | The adverse side effects related to the standard treatment for this tumor usually appear 1 day after treatment [Gli effetti collaterali associati al trattamento per questo tumore generalmente appaiono un giorno dopo il trattamento] | U | VN | NM | 488.008 | 469 | 0.263 | 0.31 | 0.551 | 500.226 | 469 | 0.154 | 0.52 | 0.438 | 513.098 | 469 | 0.078 | 0.28 | 0.404 |
| 23 | The adverse side effects related to the standard treatment for this tumor usually appear years after treatment [Gli effetti collaterali associati al trattamento per questo tumore generalmente appaiono diversi anni dopo il trattamento] | U | SN | QL | 482.879 | 469 | 0.319 | 0.49 | 0.364 | 475.172 | 469 | 0.412 | 0.16 | 0.510 | 511.176 | 469 | 0.087 | 0.43 | 0.341 |
| 24 | The duration of the adverse side effects related to the standard treatment varies over time [Gli effetti collaterali associati al trattamento per questo tumore hanno una durata variabile nel tempo] | U | NN | VG | 467.184 | 469 | 0.515 | −0.23 | 0.328 | 457.691 | 469 | 0.637 | −0.38 | 0.450 | 479.638 | 469 | 0.357 | −0.04 | 0.494 |
| 25 | This treatment takes 15 days to complete [Il trattamento si completa in 15 giorni] | U | SN | NM | 464.191 | 469 | 0.554 | −0.19 | 0.261 | 495.481 | 469 | 0.192 | 0.83 | 0.172 | <a>530.339 | <a>469 | <a>0.026* | <a>2.14* | <a>0.462 |
| 26 | This treatment takes 1 year to complete [Il trattamento si completa in 1 anno] | U | VN | NM | 485.748 | 469 | 0.287 | 0.47 | 0.382 | 486.396 | 469 | 0.28 | 0.53 | 0.494 | 473.516 | 469 | 0.433 | 0.2 | 0.483 |
| 27 | This treatment is administered in cycles [Il trattamento è somministrato in cicli] | U | NN | VG | 470.255 | 469 | 0.475 | −0.23 | 0.411 | 472.034 | 469 | 0.452 | −0.07 | 0.349 | 477.989 | 469 | 0.377 | 0.38 | 0.592 |
| 28 | This treatment is administered in a medical facility [Il trattamento è somministrato in una struttura ospedaliera] | U | NN | NO | 459.364 | 469 | 0.616 | −0.36 | 0.483 | 466.111 | 469 | 0.529 | −0.15 | 0.355 | 475.411 | 469 | 0.409 | 0.21 | 0.330 |
| 29 | During treatment, assistance might or might not be required [Durante il trattamento qualcuno ha, qualcun altro non ha bisogno di assistenza] | U | NN | VG | 448.182 | 469 | 0.748 | −0.76 | 0.435 | 451.603 | 469 | 0.71 | −0.64 | 0.526 | 471.724 | 469 | 0.456 | 0.02 | 0.441 |
| 30 | Once the whole treatment cycle is completed, assistance might or might not be required [Una volta che il trattamento è completato qualcuno ha, qualcun altro non ha bisogno di assistenza] | U | NN | VG | 460.545 | 469 | 0.601 | −0.28 | 0.420 | 456.722 | 469 | 0.649 | −0.46 | 0.392 | 474.302 | 469 | 0.423 | 0.21 | 0.434 |
| 31 | During treatment, your lifestyle might or might not be affected [Durante il trattamento il tuo stile di vita potrebbe subire dei cambiamenti (qualcuno riesce a fare la vita che faceva prima, qualche altro no)] | U | NN | VG | 468.948 | 469 | 0.492 | −0.01 | 0.468 | 479.223 | 469 | 0.362 | 0.34 | 0.474 | 458.650 | 469 | 0.625 | −0.13 | 0.498 |
| 32 | After treatment is completed, your lifestyle might or might not change from what it was prior to the disease [Dopo il trattamento il tuo stile di vita potrebbe subire dei cambiamenti rispetto a com’era prima della malattia (qualcuno riesce a fare la vita che faceva prima, qualche altro no)] | U | NN | VG | 463.806 | 469 | 0.559 | −0.17 | 0.521 | 487.053 | 469 | 0.273 | 0.31 | 0.369 | 472.034 | 469 | 0.452 | 0.43 | 0.431 |
| 33 | The treatment might or not impact on your ability to work (during the treatment phase) [Il trattamento, mentre lo fai, potrebbe influire sulla tua possibilità di andare a lavorare (qualcuno durante il trattamento non riesce ad andare a lavorare, qualcuno invece sì)] | U | NN | VG | 468.564 | 469 | 0.497 | −0.02 | 0.558 | 497.642 | 469 | 0.174 | 0.84 | 0.414 | 475.490 | 469 | 0.408 | 0.27 | 0.606 |
| 34 | Once the entire treatment cycle is completed, the treatment might or not impact on your ability to work… [Una volta che l’intero ciclo di trattamento è finito, potresti avere (ma anche no) ripercussioni sulla tua attività lavorativa (qualcuno non riesce ad tornare a lavorare come prima, qualcuno invece sì)] | U | NN | VG | 471.646 | 469 | 0.457 | −0.02 | 0.541 | 483.230 | 469 | 0.315 | 0.27 | 0.530 | 479.472 | 469 | 0.359 | 0.56 | 0.756 |
Notes: For each item, the results of two Rash Fit statistics are reported (Chisq and Infit-t). The gray background indicates the misfit items, that is, those that have been eliminated (the * indicates which of the two Rasch fit analysis results led to the item being eliminated).
Abbreviations: B, bipolar; NM, numerically expressed; NN, neither slightly negative nor very negative; NO, no quantity; QL, qualitatively expressed; SN, slightly negative; VG, vague quantity; VN, very negative; U, unipolar.